Zyrova F 10 Tablet is a combination lipid-lowering agent containing Fenofibrate 145 mg and Rosuvastatin 10 mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and modestly increases high-density lipoprotein cholesterol (HDL-C) by inhibiting the rate-limiting step in cholesterol biosynthesis. The combination therapy is beneficial in patients who require significant reduction in triglycerides and LDL-C levels, particularly those with mixed dyslipidemia or at high cardiovascular risk. Zyrova F 10 Tablet should be used as an adjunct to diet and lifestyle modifications including exercise, weight control, and smoking cessation. Caution is advised in patients with hepatic or renal impairment, and regular monitoring of liver function tests, renal parameters, and creatine kinase levels is recommended to detect potential adverse effects such as hepatotoxicity or myopathy. This medication should be prescribed under medical supervision with consideration of individual patient risk factors and therapeutic goals.